(June 22, 2023, 11:45 AM EDT) -- ALEXANDRIA, Va. — Samsung Bioepis Co. Ltd. tells the Patent Trial and Appeal Board in a June 21 petition for inter partes review (IPR) that various claims of a patented method for treating ulcerative colitis (UC) with ustekinumab “should never have issued.”...